These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10909319)

  • 21. Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study.
    Greene HL
    Am Heart J; 1994 Apr; 127(4 Pt 2):1171-8. PubMed ID: 8160597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Implantable defibrillators and antiarrhythmic drugs in patients at risk for lethal arrhythmias.
    Zivin A; Bardy GH
    Am J Cardiol; 1999 Nov; 84(9A):63R-68R. PubMed ID: 10568662
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Implantable cardioverter defibrillator compared with antiarrhythmic drug treatment in cardiac arrest survivors (the Cardiac Arrest Study Hamburg).
    Siebels J; Kuck KH
    Am Heart J; 1994 Apr; 127(4 Pt 2):1139-44. PubMed ID: 8160593
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Current treatment of ventricular arrhythmias: state of the art.
    Stevenson WG
    Heart Rhythm; 2013 Dec; 10(12):1919-26. PubMed ID: 24120875
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multicenter experience with a pectoral unipolar implantable cardioverter-defibrillator. Active Can Investigators.
    Bardy GH; Yee R; Jung W
    J Am Coll Cardiol; 1996 Aug; 28(2):400-10. PubMed ID: 8800117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Antiarrhythmic therapy in patients with heart failure].
    Faber TS; Zehender M
    Ther Umsch; 2000 May; 57(5):324-32. PubMed ID: 10859993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Indications for implantable automatic defibrillators].
    Leenhardt A; Coumel P; Thomas O; Leclercq JF; Slama R
    Arch Mal Coeur Vaiss; 1994 Jan; 87(1 Spec No):61-6. PubMed ID: 7944867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ventricular tachycardia and ventricular fibrillation.
    Srivathsan K; Ng DW; Mookadam F
    Expert Rev Cardiovasc Ther; 2009 Jul; 7(7):801-9. PubMed ID: 19589116
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia in patients with an implantable defibrillator warrants catheter ablation.
    Kuck KH
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):713-20; discussion 720. PubMed ID: 20009082
    [No Abstract]   [Full Text] [Related]  

  • 30. Ventricular arrhythmia: role of the implantable cardioverter defibrillator and radiofrequency ablation in addition to drugs.
    Fischer A; Verma R; Gomes JA; Mehta D
    Mt Sinai J Med; 2002 Sep; 69(4):197-207. PubMed ID: 12357261
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Implantable cardioverter-defibrillators.
    Aronow WS
    Am J Ther; 2010; 17(6):e208-20. PubMed ID: 19918166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term comparison of the implantable cardioverter defibrillator versus amiodarone: eleven-year follow-up of a subset of patients in the Canadian Implantable Defibrillator Study (CIDS).
    Bokhari F; Newman D; Greene M; Korley V; Mangat I; Dorian P
    Circulation; 2004 Jul; 110(2):112-6. PubMed ID: 15238454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Implantable cardioverter defibrillators in the United States: understanding the benefits and limitations of implantable cardioverter defibrillator therapy based on clinical trial results.
    Gottlieb C; Callans DJ; Marchlinski F
    Pacing Clin Electrophysiol; 1998 Nov; 21(11 Pt 1):2016-20. PubMed ID: 9826851
    [No Abstract]   [Full Text] [Related]  

  • 34. Should catheter ablation be the preferred therapy for reducing ICD shocks?: Ventricular tachycardia ablation versus drugs for preventing ICD shocks: role of adjuvant antiarrhythmic drug therapy.
    Patel C; Yan GX; Kocovic D; Kowey PR
    Circ Arrhythm Electrophysiol; 2009 Dec; 2(6):705-11; discussion 712. PubMed ID: 20009081
    [No Abstract]   [Full Text] [Related]  

  • 35. Ventricular arrhythmias and sudden cardiac death.
    John RM; Tedrow UB; Koplan BA; Albert CM; Epstein LM; Sweeney MO; Miller AL; Michaud GF; Stevenson WG
    Lancet; 2012 Oct; 380(9852):1520-9. PubMed ID: 23101719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implantable cardioverter-defibrillators for treatment of sustained ventricular arrhythmias in patients with Chagas' heart disease: comparison with a control group treated with amiodarone alone.
    Gali WL; Sarabanda AV; Baggio JM; Ferreira LG; Gomes GG; Marin-Neto JA; Junqueira LF
    Europace; 2014 May; 16(5):674-80. PubMed ID: 24481778
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reduction of antiarrhythmic drug use in patients receiving implantable cardioverter defibrillators.
    Sperry RE; Stambler BS; Wood MA; Cycan A; Ellenbogen KA
    Pacing Clin Electrophysiol; 1996 Jan; 19(1):61-4. PubMed ID: 8848378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Primary and secondary prevention of sudden cardiac death: the role of the implantable cardioverter defibrillator.
    Prystowsky EN
    Rev Cardiovasc Med; 2001; 2(4):197-205. PubMed ID: 12439369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [ESC guidelines 2015 for ventricular arrhythmias and prevention of sudden cardiac death. What is new?].
    Fink T; Kuck KH; Metzner A;
    Herz; 2015 Dec; 40(8):1034-42. PubMed ID: 26626552
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of ventricular arrhythmias after recovery from myocardial infarction.
    Mitchell LB
    Annu Rev Med; 1994; 45():119-38. PubMed ID: 7515218
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.